Long-term bevacizumab toxicity in patients with recurrent ovarian cancer

被引：0
|
作者：
Greenwade, M. [1 ]
Martin, J. Y. [2 ]
Hendrix, E. [1 ]
Ding, K. [3 ]
Dvorak, J. [1 ]
Moore, K. N. [3 ]
Goff, B. A. [2 ]
Holman, L. L. [1 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[3] Univ Oklahoma, Oklahoma City, OK USA
来源：
GYNECOLOGIC ONCOLOGY | 2017年 / 145卷
关键词：
D O I：
10.1016/j.ygyno.2017.03.224
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [1] A RETROSPECTIVE ANALYSIS OF LONG-TERM ADMINISTRATION OF BEVACIZUMAB FOR RECURRENT OVARIAN CANCER
    Tokushige, Y.
    Nakamura, A.
    Miyagawa, C.
    Higashiyama, N.
    Nakamura, A.
    Kobayashi, F.
    Yoshimizu, M.
    Nakagawa, E.
    Iwami, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 857 - 857
  • [2] Poster Session Toxicity associated with long-term bevacizumab use in patients with recurrent ovarian cancer: A multi-institutional study
    Essel, K. G.
    Martin, J. Y.
    Ramos, S. Z.
    Greenwade, M.
    Hansen, J. M.
    Krutz, M.
    Ding, K.
    Westin, S. N.
    Mathews, C. A.
    Goff, B. A.
    Moore, K. N.
    Holman, L. L.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 174 - 175
  • [3] Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination
    Ryan M. Kahn
    Govind Ragupathi
    Qin C. Zhou
    Alexia Iasonos
    Sara Kravetz
    Martee L. Hensley
    Jason A. Konner
    Vicky Makker
    William P. Tew
    Carol Aghajanian
    Paul J. Sabbatini
    Roisin E. O’Cearbhaill
    Cancer Immunology, Immunotherapy, 2023, 72 : 183 - 191
  • [4] Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination
    Kahn, Ryan M.
    Ragupathi, Govind
    Zhou, Qin C.
    Iasonos, Alexia
    Kravetz, Sara
    Hensley, Martee L.
    Konner, Jason A.
    Makker, Vicky
    Tew, William P.
    Aghajanian, Carol
    Sabbatini, Paul J.
    O'Cearbhaill, Roisin E.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (01) : 183 - 191
  • [5] LONG-TERM TOXICITY OF BEVACIZUMAB IN PATIENTS WITH NEUROFIBROMATOSIS 2
    Merker, Vanessa
    Slusarz, Katie
    Muzikansky, Alona
    Francis, Sanjeev
    Plotkin, Scott
    NEURO-ONCOLOGY, 2013, 15 : 121 - 121
  • [6] The efficacy and toxicity of bevacizumab plus genicitabine in patients with recurrent ovarian cancer
    Bevis, K. S.
    Numnum, T. M.
    Shipman, K. A.
    Makhija, S.
    Barnes, M. N.
    Straughn, J.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S119 - S120
  • [7] Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
    Katherine M. Slusarz
    Vanessa L. Merker
    Alona Muzikansky
    Sanjeev A. Francis
    Scott R. Plotkin
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1197 - 1204
  • [8] Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
    Slusarz, Katherine M.
    Merker, Vanessa L.
    Muzikansky, Alona
    Francis, Sanjeev A.
    Plotkin, Scott R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1197 - 1204
  • [9] Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
    Swisher, Elizabeth M.
    Kristeleit, Rebecca S.
    Oza, Amit M.
    Tinker, Anna, V
    Ray-Coquard, Isabelle
    Oaknin, Ana
    Coleman, Robert L.
    Burris, Howard A.
    Aghajanian, Carol
    O'Malley, David M.
    Leary, Alexandra
    Welch, Stephen
    Provencher, Diane
    Shapiro, Geoffrey, I
    Chen, Lee-May
    Shapira-Frommer, Ronnie
    Kaufmann, Scott H.
    Goble, Sandra
    Maloney, Lara
    Kwan, Tanya
    Lin, Kevin K.
    McNeish, Iain A.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 490 - 497
  • [10] Long-term topotecan therapy in recurrent or persistent ovarian cancer
    Cormio, G.
    Loizzi, V.
    Gissi, F.
    Camporeale, A.
    De Mitri, P.
    Leone, L.
    Putignano, G.
    Selvaggi, L.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2011, 32 (02) : 153 - 155
12345